In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)

BMC Bioinformatics

Volumn 12, Issue SUPPL. 13, 2011, Pages

  Tambunan, Usman S F ^a   Bramantya, N ^a   Parikesit, Arli A ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING AFFINITIES; CANCER THERAPY; CERVICAL CANCERS; CLASS II; DRUG SCORE; HDAC INHIBITORS; HISTONE DEACETYLASES; HUMAN PAPILLOMA VIRUS; IN-SILICO; INHIBITION ACTIVITY; LOW TOXICITY; ORAL BIOAVAILABILITIES; POTENTIAL INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACIDS;

BINDING ENERGY; BIOCHEMISTRY; DOCKING; ENZYME INHIBITION; TOXICITY; VIRUSES;

ORGANIC ACIDS;

HUMAN PAPILLOMAVIRUS;

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; VORINOSTAT;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR DYNAMICS; STRUCTURE ACTIVITY RELATION;

HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP;

MLCS; MLOWN;

EID: 84864035147     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-S13-S23     Document Type: Article

References (16)

1. World Health Organization Cervical Cancer Screening in Developing Countries. 2002, Geneva: World Health Organization, World Health Organization.
2. Tambunan USF, Parikesit AA, Tochary T, Sugiono D. In silico study of post translation modification of Chimeric vaccine design by using Virus like particles of HPV with capsid virion L1. Makara, Sains 2007, 11(2):56-62.
3. Irianiwati, Utoro T, Ediati FX. The correlation between HPV infection and p53, pRb, Kl-67 as well as tunnel expression of cervical carcinoma. Berkala Ilmu Kedokteran 2007, 39(3):115-121.
4. Tambunan USF, Wulandari EK. Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculation and descriptor analysis. BMC Bioinformatics 2010, 11:7-16. 10.1186/1471-2105-11-7, 2806359, 20051126.
5. Subha K, Kumar GR. Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis. Bioinformation 2008, 3(5):218-222. 10.6026/97320630003218, 2646192, 19255637.
6. Dong Hoon K, Minjung K, Ho Jeong K. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 2003, 36(1):110-119. 10.5483/BMBRep.2003.36.1.110, 12542981.
7. Roffey J. Bioisosteres in medicinal chemistry. Maybridge MedChem 1997, 1:23-44.
8. Pirali T, Pagliai F, Mercurio C, Boggio R, Canonico PL, Sorba G, Tron GC, Genazzani AA. Triazole-modified histone deacetylase inhibitors as a rapid route to drug discovery. J Comb Chem 2008, 10(5):624-627. 10.1021/cc800061c, 18598089.
9. He R, He R, Chen Y, Chen Y, Ougolkov AV, Zhang JS, Savoy DN, Billadeau DD, Kozikowski AP. Synthesis and biological evaluation of triazole-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents. Journal of Medicinal Chemistry 2010, (53):1347-1356.
10. Tambunan USF, Alamudi S. Designing cyclic peptide inhibitor of dengue virus NS3-NS2B protease by using molecular docking approach. Bioinformation 2010, 5(6):250-254. 10.6026/97320630005250, 3055701, 21364826.
11. Copeland, Robert A. Evaluation of Enzyme Inhibitors in Drug Discovery. 2005, New Jersey: Wiley Interscience.
12. Lindemann RK, Johnstone RW. Histone deacetylase inhibitors: promising candidates for chemotherapeutic drugs. Gene Ther Mol Biol 2004, 8:61-74.
13. Alonso H, Bliznyuk AA, Gready JE. Combining docking and molecular dynamic simulation in drug design. Med Res Rev 2006, 26(5):531-568. 10.1002/med.20067, 16758486.
14. Difei W. Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem 2009, 9(3):241-256. 10.2174/156802609788085287, 2766262, 19355989.
15. Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkühler C, Gallinari P, Carfí A. Structural and functional analysis of the human HDAC 4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 2008, 283(39):26694-26704. 10.1074/jbc.M803514200, 3258910, 18614528.
16. Stroganov OV, Novikov FN, Stroylov VS, Kulkov V, Chilov GG. Lead finder: an approach to improve accuracy of protein-ligand docking, binding energy estimation, and virtual. J Chem Inf Model 2008, 48(12):2371-2385. 10.1021/ci800166p, 19007114.